Brevan Howard Capital Management’s AbCellera Biologics ABCL Stock Holding History

Brevan Howard Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65.7K	Buy	+18,824	New	+$67.7K	﹤0.01%	2067
2025 Q4	–	Sell	-54,355	Closed	-$273K	–	1718
2025 Q3	$273K	Sell	54,355 -11,252	-17%	-$49.6K	﹤0.01%	1610
2025 Q2	$225K	Sell	65,607 -75,718	-54%	-$188K	﹤0.01%	1668
2025 Q1	$315K	Buy	141,325 +57,806	+69%	+$166K	﹤0.01%	851
2024 Q4	$245K	Buy	83,519 +70,633	+548%	+$197K	﹤0.01%	846
2024 Q3	$33.5K	Buy	+12,886	New	+$35.7K	﹤0.01%	1101

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Brevan Howard Capital Management's ABCL Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in AbCellera Biologics (ABCL) in Q1 2026: 18,824 shares worth $65.7K. The stake represents ﹤0.01% of the portfolio and ranks #2067 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in ABCL as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in ABCL in Q3 2024 and has held it in 6 quarters since. The position peaked at $315K in Q1 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Brevan Howard Capital Management held 18,824 shares of AbCellera Biologics worth $65.7K as of Q1 2026.
AbCellera Biologics was a new Brevan Howard Capital Management position in Q1 2026.
AbCellera Biologics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #2067 holding.
Brevan Howard Capital Management first reported a position in AbCellera Biologics in Q3 2024 and has held it in 6 quarters since.
Brevan Howard Capital Management's AbCellera Biologics position peaked at $315K in Q1 2025.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.